Oncology – Head and Neck
Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.
23 Jun, 2022 | 09:54h | UTC
Health Technology Assessment: Molecular testing for thyroid nodules of indeterminate cytology.
25 May, 2022 | 10:42h | UTC
M-A: Complication rates of total thyroidectomy vs. hemithyroidectomy for treatment of papillary thyroid microcarcinoma.
11 May, 2022 | 10:59h | UTCComplication Rates of Total Thyroidectomy vs Hemithyroidectomy for Treatment of Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)
Commentary on Twitter
In this systematic review and #meta-analysis, complications in the surgical management of micropapillary #thyroid carcinoma increased with the extent of surgery performed, although complications and recurrence were low for both operations. https://t.co/Itf14o38Vu @wiscsurgery
— JAMA Otolaryngology – Head & Neck Surgery (@JAMAOto) May 6, 2022
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.
5 May, 2022 | 10:16h | UTC
RCT: Effect of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy.
27 Apr, 2022 | 07:44h | UTCEffect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized trial of efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma demonstrates that capecitabine maintenance therapy improved survival & was associated with manageable toxicities. https://t.co/Ay2WZ7ZuCN pic.twitter.com/sZJ6qfzCOY
— JAMA Oncology (@JAMAOnc) February 17, 2022
RCT: Sintilimab vs. placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma.
20 Apr, 2022 | 09:28h | UTC
Commentary on Twitter
Compared with placebo, sintilimab in combination with chemo showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma, finds study https://t.co/m8Gn3SBmCu
— The BMJ (@bmj_latest) April 19, 2022
Development and validation of machine learning models for predicting occult nodal metastasis in early-stage oral cavity squamous cell carcinoma.
20 Apr, 2022 | 09:14h | UTC
Commentary on Twitter
In this diagnostic modeling study, #MachineLearning models built with multi-institutional data showed potential to reduce morbidity from elective neck dissections with similar cancer outcomes in patients with early-stage oral cavity squamous cell carcinoma https://t.co/aRktgc0ms6
— JAMA Network Open (@JAMANetworkOpen) April 13, 2022
Development and validation of a decision analytical model for posttreatment surveillance for patients with oropharyngeal carcinoma.
14 Apr, 2022 | 07:52h | UTC
RCT: Effect of induction chemotherapy with Paclitaxel, Cisplatin, and Capecitabine vs. Cisplatin and Fluorouracil on failure-free survival for patients with stage IVA to IVB Nasopharyngeal Carcinoma.
28 Mar, 2022 | 08:36h | UTCEffect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma — Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS – MedPage Today (free registration required)
Commentary on Twitter
Phase 3 randomized trial of paitents with stage IVA to IVB nasopharyngeal carcinoma shows that induction chemotherapy w 2 cycles of paclitaxel/cisplatin/capecitabine improved failure-free survival vs. cisplatin/5-FU before concurrent chemoradiation. https://t.co/YYEvFsTxgd pic.twitter.com/7qbSXLWCE1
— JAMA Oncology (@JAMAOnc) March 24, 2022
SEOM-TTCC clinical guideline in nasopharynx cancer.
25 Mar, 2022 | 08:20h | UTCSEOM-TTCC clinical guideline in nasopharynx cancer (2021) – Clinical and Translational Oncology
Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.
17 Mar, 2022 | 08:16h | UTCAuthor Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations
Related:
Three-year follow-up of 2-dose versus 3-dose HPV vaccine
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
RCT: In patients with low-risk thyroid cancer, thyroidectomy without ablation radioiodine was noninferior to thyroidectomy with ablation radioiodine at 3 years.
10 Mar, 2022 | 10:59h | UTCThyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: New research casts doubt on a cornerstone of thyroid cancer treatment – STAT
Commentary on Twitter
In RCT involving patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, a follow-up strategy that did not involve the use of radioiodine was noninferior to the use of radioiodine in the response to treatment at 3 years. https://t.co/RaJL3tdE4T pic.twitter.com/8nIPw50nkg
— NEJM (@NEJM) March 9, 2022
RCT: Elective upper-neck vs. whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma.
9 Mar, 2022 | 08:17h | UTCElective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Elective Upper-Neck vs Whole-Neck Irradiation in Nasopharyngeal Carcinoma – The ASCO Post
Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma— Phase III trial also shows that upper-neck irradiation leads to fewer late toxicities – MedPage Today (link to abstract – $ for full-text)
RCT: In operated patients with head and neck cancer, chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin and is associated with reduced toxicity.
3 Mar, 2022 | 08:11h | UTC
Commentary from the author on Twitter
Dear friends,
Finally, the results of JCOG1008, post operative CRT (weekly CDDP vs. 3-weekly CDDP) has published on Journal of Oncology.
Weekly CDDP+RT is a new treatment option with equal efficacy and better safety profile.
Please check the manuscript!!https://t.co/XG6mkGeo4Y— Naomi Kiyota (@kiyota_naomi) March 1, 2022
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.
1 Mar, 2022 | 08:30h | UTCHPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Consensus Statement: Head and neck cancer survivorship.
16 Feb, 2022 | 08:49h | UTCRelated:
Head and Neck Cancer Survivorship Care Guideline
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
11 Feb, 2022 | 08:23h | UTC
RCT: Apatinib improves outcomes compared to placebo in patients with locally advanced or metastatic, radioactive iodine–refractory differentiated thyroid cancer.
10 Feb, 2022 | 09:56h | UTC
Commentary on Twitter
Apatinib offered significant clinical benefits in terms of both prolonged progression-free survival and overall survival in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. https://t.co/I14AyxKZNS
— JAMA Oncology (@JAMAOnc) December 16, 2021
Systematic Review: Chemotherapy for the treatment of oral cavity and oropharyngeal cancer.
13 Jan, 2022 | 08:14h | UTCSummary: Chemotherapy for mouth and throat cancer – Cochrane Library
Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.
14 Jul, 2021 | 11:07h | UTCNews release: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Commentaries: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian AND Expert reaction to study of alcohol and cancer – Science Media Centre
ASCO Guideline: Management of Salivary Gland Malignancy
28 Apr, 2021 | 08:13h | UTCManagement of Salivary Gland Malignancy: ASCO Guideline – Journal of Clinical Oncology
Survey: Despite guideline recommendations, many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone
23 Apr, 2021 | 08:13h | UTCTSH Suppression for Papillary Thyroid Cancer: A Physician Survey Study – Thyroid (link to abstract – $ for full-text)
Commentary on Twitter
Hot off the press. We found that many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone, emphasizing the need for more research to better guide thyroid cancer management. @AmThyroidAssn @UMRogelCancer https://t.co/iU3ObzQxBQ
— Maria Papaleontiou, MD (@MariaPapaleont1) March 30, 2021
Guidelines for Management of Patients with Anaplastic Thyroid Cancer
20 Apr, 2021 | 05:24h | UTCCommentary: ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer – HealthDay
M-A: Chemotherapy and radiotherapy in locally advanced head and neck cancer
15 Apr, 2021 | 06:29h | UTC
Commentary on Twitter
What is the best treatment in locally advanced HN Cancer?
Our latest individual patient data network meta-analysis available here for free @TheLancetOncol: https://t.co/UuFvjpKO6I
Many limitations but by far the largest work on the topic (115 RCT, 29000 pts).
#radonc #hncsm pic.twitter.com/eNYHbxsB4Q
— Pierre Blanchard, MD (@PBlanchardMD) April 14, 2021
Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study
5 Mar, 2021 | 08:10h | UTCGlobal patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Commentaries: Global thyroid cancer overdiagnosis in children and adolescents – MDEdge (free registration required) AND Global Thyroid Cancer Overdiagnosis in Children and Adolescents – Medscape (free registration required)
Commentary on Twitter
New #IARCpaper shows the incidence of thyroid cancer in children & adolescents, a rare condition everywhere before 2000, has increased rapidly in recent years in many countries, & suggests overdiagnosis is likely to be the main driver of these increases https://t.co/1ct8iEJSty pic.twitter.com/JIjBBAyKNv
— IARC (@IARCWHO) January 20, 2021